CDMRP Neurofibromatosis Exploration-Hypothesis Development Award
ID: 355147Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355147
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Neurofibromatosis Exploration-Hypothesis Development Award to support innovative research in neurofibromatosis (NF) types 1 and 2, as well as schwannomatosis. This grant aims to facilitate high-risk, high-reward studies that can lead to groundbreaking advancements in NF understanding, diagnosis, and treatment, particularly benefiting military personnel and their families. The total funding available for this program is $1,120,000, with up to $100,000 awarded per project over a two-year period, and applications must be submitted in two phases: a pre-application by September 12, 2024, and a full application by October 3, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524NFRPEHDA_GG.pdf
    The Department of Defense (DOD) is announcing the FY24 Neurofibromatosis Exploration-Hypothesis Development Award as part of the Neurofibromatosis Research Program. This funding aims to support innovative research related to neurofibromatosis (NF) types 1 and 2 and schwannomatosis, ultimately improving diagnosis and treatment. The award offers up to $100,000 over a two-year period, with a total appropriation of $25 million for FY24. Applications must undergo a two-step submission process, including a pre-application due by September 12, 2024, and full applications due by October 3, 2024. Key areas of emphasis include advancements in NF understanding, technological innovation, and health services research pertinent to military personnel and their families. Applicants are encouraged to foster collaboration across disciplines and organizations. Peer review will evaluate the merit based on innovation, research strategy, and potential impact. Compliance with institutional requirements, data sharing, and rigorous study design is mandated. The program seeks to facilitate high-risk, high-reward research that significantly impacts NF research and patient care, demonstrating DOD's commitment to addressing critical health challenges faced by service members and the broader community.
    Similar Opportunities
    DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRDC), has announced the FY23-FY27 Broad Agency Announcement (BAA) for Extramural Medical Research, which is open for submissions from October 1, 2022, to September 30, 2027. This opportunity invites innovative research proposals that address critical military medical challenges, particularly in the areas of Military Infectious Diseases, Combat Casualty Care, and Military Operational Medicine, with a focus on enhancing medical practices for both military personnel and civilians. The BAA emphasizes the importance of collaboration with Department of Defense and Department of Veterans Affairs resources and requires adherence to strict submission guidelines via Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Interested applicants can submit pre-proposals at any time during the five-year period, with full proposals invited based on initial submissions, and should direct inquiries to the CDMRP Help Desk at help@eBRAP.org.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    Department of Defense HIV/AIDS Prevention Program
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering a federal grant opportunity titled the Department of Defense HIV/AIDS Prevention Program (DHAPP). This program aims to save lives and prevent HIV infections by supporting the development of interventions and programs within military health systems, particularly in foreign countries, to achieve HIV/AIDS epidemic control. The DHAPP focuses on enhancing military capacity for ownership and behavioral change, aligning with national strategies, and ensuring sustainable HIV prevention and treatment services. Interested applicants can reach out to Ebony Simmons at ebony.s.simmons.civ@health.mil or by phone at 301-619-2105 for further information. The application deadline is September 18, 2027, with an expected seven awards to be made under this cooperative agreement, which does not require cost sharing or matching.
    Airman Readiness Medical Research (ARMR) Hybrid BAA
    Air Force -- Research Lab
    The Air Force Research Laboratory (AFRL) is soliciting proposals for the Airman Readiness Medical Research (ARMR) program through a Hybrid Broad Agency Announcement (BAA) designated FA8650-20-S-6008. The primary objectives of this initiative are to conduct medical research aimed at optimizing the health and performance of Airmen, focusing on ensuring medical availability and understanding the effects of various operational environments on Airman well-being. This program is critical for enhancing the operational readiness of military personnel, particularly in high-demand mission scenarios, with key research areas including aeromedical evacuation, cognitive performance, and exposure health. The total funding available for this program is estimated at $480 million, with individual awards ranging from $50,000 to $49 million. Interested parties are encouraged to submit white papers by May 1, 2025, and can direct inquiries to Amber A. Taylor at amber.taylor.9@us.af.mil.
    Funding Opportunity Title:Deployed Warfighter Protection (DWFP) Program for the Protection of Deployed Military Personnel from Threats Posed by Arthropod Disease Vectors
    Department of Defense
    The Department of Defense is offering a funding opportunity through the Fiscal Year 2025 Deployed Warfighter Protection (DWFP) Program, aimed at safeguarding military personnel from threats posed by arthropod disease vectors. The program seeks innovative research proposals focused on developing new insecticides, personal protection technologies, and improved vector control strategies, with applications required to address specific research areas such as bite prevention, vector control, and diagnostics. This initiative is crucial for enhancing health protection in military operations and has a total estimated funding of $5 million, with individual awards capped at $975,000 over three years. Interested applicants must submit a pre-application by October 4, 2024, and a full application by January 28, 2025; for further inquiries, contact Scott I. Hoffman at scott.i.hoffman2.civ@army.mil or call 1-520-671-1470.
    Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders" (PAR-25-327), aimed at supporting Investigational New Drug (IND)-enabling studies and preparations for First-in-Human (FIH) clinical trials. This initiative focuses on advancing innovative gene-based therapies, such as oligonucleotides and viral vector approaches, for ultra-rare disorders affecting fewer than 6,000 patients, with an emphasis on projects that demonstrate robust proof of concept data and readiness for clinical trials. Eligible applicants include a wide range of organizations, including higher education institutions and various nonprofit and for-profit entities, with applications requiring detailed project planning and compliance with Good Manufacturing Practices (GMP). The application period opens on January 9, 2025, with a close date of October 8, 2027, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for research focused on the neurological effects of infection-associated chronic illnesses, including conditions like Neuro-PASC, post-treatment Lyme Disease, and ME/CFS. This initiative aims to promote understanding of the neuropsychiatric manifestations of these illnesses, with a particular interest in projects that explore common mechanisms across multiple conditions, although applications can focus on individual illnesses as well. The anticipated funding amount for this grant is up to $500,000, with the NOFO expected to be published in Fall 2024 and applications due in Winter 2025. Interested applicants should prepare to submit their proposals by the estimated closing date of February 3, 2025, with awards expected to be made by December 1, 2025.
    US Army Combat Capabilities Development Command Broad Agency Announcement
    ACC APG - Natick
    The US Army Combat Capabilities Development Command (CCDC) is inviting proposals through its Broad Agency Announcement (BAA) for research and development funding, managed by the ACC APG - Natick. This opportunity allows unrestricted applicants to submit white papers and proposals for grants and assistance agreements, focusing on various areas of interest outlined in the BAA solicitation document. The initiative is crucial for advancing the capabilities of the Army, with an expected 50 awards to be made. Interested parties should note that the submission deadline is February 28, 2025, and can reach out to Shawn P. Haubner at shawn.p.haubner.civ@mail.mil or by phone at 508-206-2067 for further information.
    Tactical Behaviors for Autonomous Maneuver
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity through the Tactical Behaviors for Autonomous Maneuver Collaborative Research Program (TBAM-CRP) aimed at enhancing the capabilities of robotic and autonomous systems (RAS) for military operations in complex environments. This program seeks proposals that develop coordinated and adaptive behaviors for small groups of autonomous agents, focusing on innovative maneuver tactics and strategies to operate effectively in multi-domain operations against peer adversaries. The TBAM-CRP is critical for advancing military capabilities, leveraging new technologies in robotics and autonomous systems to improve situational awareness and operational effectiveness on the battlefield. Interested applicants, including institutions of higher education and for-profit organizations, are invited to submit proposals by April 24, 2024, with funding amounts ranging from $100,000 to $2.3 million available per award. For further inquiries, applicants can contact Christopher D. Justice at usarmy.adelphi.devcom-arl.mbx.tbam-crp-questions@army.mil.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)," aimed at encouraging exploratory research to develop advanced microphysiological systems (MPS) that accurately replicate complex human nervous system architectures. This initiative seeks to facilitate studies on nervous system development, function, and aging, particularly in relation to neurological diseases. The R21 grant allows for a budget of up to $275,000 over two years, with applications opening on January 16, 2025, and a submission deadline of January 7, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.